Close


2026年10月12日

Regenerative Medicine delegation from Japan 

You can download the list as pdf .

  1. Jun Miyagawa, Assistant to the Chairman – Nakanoshima Qross and President & CEO of Miracle Science Innovation Inc

 Key interest areas:

Regenerative-medicine ecosystem hub; startup & venture support

 Website:Nakanoshima Qross (English)

Nakanoshima Qross(中之島クロス) (日本語)

  1. Hiroki Iguchi, Marketing & Business Development Manager, Cell Culture Business Group/Life Science Business Development Department – Sekisui Chemical 

Key interest areas:

member of the value chain consortium for development of Mass Cell Culture System (VMaCS); cell culture scaffold material Ceglu™; stable cell manufacturing

Website: SEKISUI CHEMICAL CO.,LTD

  1. Keiko Okamura, Director, General Manager of Business Management Division – Gojo Medical

 Key interest areas:

member of the value chain consortium for development of Mass Cell Culture System (VMaCS); ultra-low-temperature logistics & asset-based 3PL; pharma/medical device transport

Website : https://gojyo-med.co.jp

  1. Kazuo Omori, President & CEO – Revascular Bio Inc (Bio venture from Osaka University)

 Key interest areas:

Vascular endothelial stem cells; therapies for vascular disorders; regenerative-medicine drug discovery

Website: Revascular Bio

  1. Kazuyoshi Hirao, Director & Chief Business Officer – Quorips

Key interest areas:

iPS cell-derived cardiomyocyte sheets; EMA; European expansion;  value chain consortium for development of Mass Cell Culture System (VMaCS) lead

Website:Cuorips Inc. | Pioneering the Future of Cell Therapeutics

  1. Nariaki Yanagawa, Assistant Manager Regenerative Engineering R&D Department – Saraya

Key interest areas:

Hygiene & infection control; cell manufacturing environments; overseas business

Website: SARAYA – Home

  1. Daisuke Akabane, Sr. Manager Clinical Team/Business Development Department – VC cell therapy Inc. (Vision Care)

Key interest areas:

iPS-derived retinal pigment epithelium cells; Kobe Eye Center; ophthalmic regenerative medicine

Website: HOME | 株式会社 VC Cell Therapy

  1. Kasane Ogura, Advanced Medical Business Development Collaboration Office – iPS Portal

Key interest areas: iPS cell R&D and commercialization support; disease specific iPS cell banking; regenerativemedicine services (Kyoto/CiRA ecosystem)

Website: iPS Portal, Inc

  1. Masaaki Shimokoshi , General Manager International Program Department – Japan Asia Medical Investment Co., Ltd (Japan entity of Hong Kong Asia  Medical Group) / Sapporo Cardio Vascular Clinic

Key interest areas:

Heart centers and hospitals in China, HK, Japan, and Indonesia. Candidate clinical site for cardiac cell therapy implementation

Website: Home | HK Asia Medical Group

  1. Hajime Oji , Digital Healthcare and Future Cities Division, Medical & Healthcare and Smart City Business Division – NEC Corporation / Fones Life Co., Ltd. (TBC) 

Website: 

  1. Representative from Chitose Bio (TBC)

Specializes in technological development aimed at maximizing breeding and cultivation technologies for microorganisms, microalgae, and cultured cells to a commercial level and bringing them to market. The company collaborates with Fujifilm in the biopharmaceutical field. The company contributes to gene therapy through initiatives such as the development of HAT cell lines (collaborating with Osaka University).

Website: CHITOSE Group | Family of Biotechnology Companies Leading the Global Bioeconomy

2026年10月12日